Summary:
EMBOLD: Evaluating a Potential Approach for Progressive Forms of MS
What’s next in research for non-active progressive MS
The EMBOLD Study is evaluating a new potential investigational treatment designed for progressive MS that gets worse with time but doesn’t include relapses (non-active primary and secondary progressive multiple sclerosis).
EMBOLD at a Glance
- Up to 200 participants
- Five years of participation
- All participants will receive the investigational treatment at certain points in the study.
You may be eligible if:*
- You are aged 18 to 60 and diagnosed with progressive multiple sclerosis without relapses
- You’ve never tried Lemtrada® (alemtuzumab), Mavenclad® (cladribine), stem cell transplant, or EBV T-cell therapy
- You are able to walk 30 feet or more with or without the help of a cane or walker
*Other eligibility criteria will apply.
All participants will receive the investigational treatment and study-related care and monitoring at no cost. Travel support and reimbursements may also be available.